German Cancer Society, Kuno-Fischer-Strasse 8, Berlin, 14057, Germany.
OnkoZert, Neu-Ulm, Germany.
World J Urol. 2021 Jan;39(1):11-25. doi: 10.1007/s00345-019-02949-7. Epub 2019 Sep 24.
For patients with prostate cancer, validated and reliable instruments are essential for measuring patient-reported outcomes. The aim of this study was to validate the German version of the widely established Expanded Prostate Cancer Index Composite with 26 items (EPIC-26).
A German translation of the original questionnaire was tested in 3094 patients with localized or locally advanced (any T, any N and M0) prostate cancer with treatment intent (including radical prostatectomy, brachytherapy, active surveillance, watchful waiting). They completed the EPIC-26 questionnaire before treatment. A total of 521 of them also completed a questionnaire 12 months afterward. Internal consistency, sensitivity to change, and construct validity were assessed.
The internal consistency of all domains was sufficient (Cronbach's alpha between 0.64 and 0.93). Item-to-scale correlation coefficients showed acceptable associations between items and their domain score (all > 0.30), with the lowest scores for "bloody stools" (r = 0.37) and "breast problems" (r = 0.32). Confirmatory and exploratory factor analysis confirmed the five-dimension structure of the EPIC-26 (comparative fit index 0.95).
Psychometric evaluation suggests that the German version of the EPIC-26 is a well-constructed instrument for measuring patient-reported health-related symptoms in patients with prostate cancer.
对于前列腺癌患者，有效的和可靠的工具对于测量患者报告的结果是至关重要的。本研究的目的是验证广泛应用的 26 项扩展前列腺癌指数综合量表（EPIC-26）的德语版本。
对 3094 名有局限性或局部进展性（任何 T、任何 N 和 M0）前列腺癌治疗意向的患者（包括根治性前列腺切除术、近距离放射治疗、主动监测、观察等待）进行了原始问卷的德语翻译测试。他们在治疗前完成了 EPIC-26 问卷。其中共有 521 名患者在 12 个月后也完成了一份问卷。评估了内部一致性、变化敏感性和结构有效性。
所有领域的内部一致性都足够（克朗巴赫的 alpha 值在 0.64 到 0.93 之间）。项目与量表之间的相关系数显示出项目与其领域得分之间的可接受关联（均>0.30），其中“血便”（r=0.37）和“乳房问题”（r=0.32）的得分最低。验证性和探索性因子分析证实了 EPIC-26 的五维度结构（比较拟合指数 0.95）。
心理测量评估表明，EPIC-26 的德语版本是一种良好的结构工具，可用于测量前列腺癌患者的健康相关症状。
